D. Kremastinos

The PTHrP/PTH.1-R bioregulation system in cardiac hypertrophy: possible therapeutic implications.

M. Koutsilieris, E. Diamanti-Kandarakis, A. Halapas, 2006, In vivo.

Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.

T Mavromoustakos, E. Iliodromitis, J. Matsoukas, 2001, Bioorganic & medicinal chemistry.

A case of Adamantiadis-Behçet's syndrome presenting as myocardial infarction.

A. Iliopoulos, C. Georganas, D. Kremastinos, 1993, Clinical and experimental rheumatology.

Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients

J. Lekakis, D. Vlahakos, P. Flevari, 2013, Journal of hypertension.

QT‐interval dispersion in acute myocardial infarction is only shortened by thrombolysis in myocardial infarction grade 2/3 reperfusion

E. Iliodromitis, D. Cokkinos, V. Voudris, 2003, Clinical cardiology.

Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists.

Panagiotis Zoumpoulakis, Simona Golic Grdadolnik, Ilze Mutule, 2002, Bioorganic & medicinal chemistry letters.

Conformational and biological studies for a pair of novel synthetic AT1 antagonists: stereoelectronic requirements for antihypertensive efficacy.

T Mavromoustakos, S. Grdadolnik, A. Zoga, 2003, Journal of pharmaceutical and biomedical analysis.